Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2022 | $28.00 → $5.00 | Buy → Neutral | Goldman |
| 1/13/2022 | $25.00 → $19.00 | Buy | HC Wainwright & Co. |
| 11/19/2021 | $55.00 → $26.00 | Overweight | Piper Sandler |
| 11/10/2021 | $8.00 → $7.00 | Market Perform | SVB Leerink |
| 10/21/2021 | $18.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink |
| 9/20/2021 | $40.00 → $29.00 | Buy | Truist Securities |
| 9/20/2021 | $37.00 → $25.00 | Buy | HC Wainwright & Co. |
| 9/17/2021 | $45.00 → $11.00 | Outperform → Neutral | Wedbush |
SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)
SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)
SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada
- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NE
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies' complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the w
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2's common stock to one non-executive new hire. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.77, which represents the closing market price
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2's common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.50, which represents the closing mar
15-12G - TCR2 THERAPEUTICS INC. (0001750019) (Filer)
EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)
EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Sensus Healthcare The Trade: Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Samuel O'Rear acquired a total 20,000 shares an average price of $2.99. To acquire these shares, it cost around $59.85 thousand. The company’s President and General Counsel also bought
TCR2 Therapeutics (NASDAQ:TCRR) reported its Q1 earnings results on Thursday, May 11, 2023 at 06:30 AM. Here's what investors need to know about the announcement. Earnings TCR2 Therapeutics missed estimated earnings by 51.47%, reporting an EPS of $-1.03 versus an estimate of $-0.68. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.77 which was followed by a 5.63% increase in the share price the next day. Listen to the earnings announcement yourself by clicking here. To track all earnings releases for TCR2 Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content eng
TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.03) per share. This is a 35.53 percent decrease over losses of $(0.76) per share from the same period last year.
4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)
4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)
4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)
Goldman downgraded TCR2 Therapeutics from Buy to Neutral and set a new price target of $5.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $19.00 from $25.00 previously
Piper Sandler resumed coverage of TCR2 Therapeutics with a rating of Overweight and set a new price target of $26.00 from $55.00 previously
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. "We are excited to announce Eric Sullivan is joining the TCR2 team as Chief Financial Officer," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "Eric brings a tremendous breadth of financial,
CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities. "We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR2 as she has proven throughout her career an ability to work closely with multiple commercial function
CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde's arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2